TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02974257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine 500mg IV twice daily for 2 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mL normal saline IV every 12 hours for 2 days
Study: NCT03170336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
Study: NCT03490669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-1
Description: humanized monoclonal antibody for intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-1
Description: humanized monoclonal antibody for intravenous administration
Study: NCT02004054

Intervention type: OTHER
Intervention: measure of pupil diameter
Description: The measure will use infra-red cameras
Study: NCT04608097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task intervention
Description: A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo
Description: A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
Study: NCT00815984

Intervention type: PROCEDURE
Intervention: measurements of lung function tests
Description: Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
Study: NCT01801046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo HMMACT with G-PBSC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02517112

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular parameters measurements
Description: with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D-BCG sensor
Study: NCT02074215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Aerobic exercises + dual task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretch exercise
Description: Stretch exercise
Study: NCT03227627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalStim
Description: One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
Study: NCT00461565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Study: NCT04355676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: 20 mg selinexor oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: 20 mg selinexor oral tablet.
Study: NCT01951209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg orally twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg orally twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT05642936

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: didactic health education control
Description: didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation technique
Description: a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
Study: NCT01425840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
Study: NCT02063815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fissure sealant application

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fissure sealant application
Study: NCT02107469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sida cordifolia roots
Description: Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Description: Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sida cordifolia roots extract
Description: gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri extract
Description: gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sida cordifolia placebo
Description: 300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phyllanthus niruri placebo
Description: 300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
Study: NCT03475433

Intervention type: DEVICE
Intervention: Actigraphy device
Description: Both groups will receive an actigraphy device that will passively measure their movement data.

Intervention type: DEVICE
Intervention: Actigraphy device
Description: Both groups will receive an actigraphy device that will passively measure their movement data.
Study: NCT01757379

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C-labeled Acetate
Description: 400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C-labeled propionate
Description: 340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C-labeled butyrate
Description: 990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 15 g of inulin dissolved in 200 ml of water
Study: NCT00835796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg tablets
Description: 1 x 5 mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROSCAR® 5mg tablets
Description: 1 x 5 mg, single dose fasting
Study: NCT06516172

Intervention type: OTHER
Intervention: Comprehensive disease-specific rehabilitation
Description: Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes.

Intervention type: OTHER
Intervention: Comprehensive disease-specific rehabilitation
Description: Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes.

Intervention type: OTHER
Intervention: Comprehensive disease-specific rehabilitation
Description: Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes.

Intervention type: OTHER
Intervention: Comprehensive disease-specific rehabilitation
Description: Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes.
Study: NCT01230229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting
Description: The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best medical treatment
Description: Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
Study: NCT02131077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-TI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02260063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinastine tablets
Study: NCT01116791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)
Description: * CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~* HIPC is administered immediately after CRS
Study: NCT04599842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
Study: NCT03302949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacprodan® DI-8090
Description: Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
Study: NCT03413774

Intervention type: PROCEDURE
Intervention: vaginal swab
Description: high vaginal and Endocrvical swabs for bacterial, protozoal and chlamydial infection- examined by PCR
Study: NCT03862573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study: NCT03900039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Highly Cross Linked Polyethylene and oxidized zirconium femoral head
Description: Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Highly Cross Linked Polyethylene and oxidized zirconium femoral head
Description: Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Highly Cross Linked Polyethylene and oxidized zirconium femoral head
Description: Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Highly Cross Linked Polyethylene and oxidized zirconium femoral head
Description: Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads
Study: NCT02533466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride + potassium nitrate
Description: Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potassium nitrate
Description: Experimental toothpaste containing 5% potassium nitrate
Study: NCT01820091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
Study: NCT01063244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: foley balloon only
Description: place foley balloon only in cervix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: foley balloon with weight attached
Description: foley balloon with 1000cc IV bag attached
Study: NCT02392689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: Procalcitonin guided antibiotic therapy
Study: NCT03638063

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine Triphosphate
Description: Adenosine Triphosphate aerosol

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine Triphosphate
Description: Adenosine Triphosphate aerosol

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine Triphosphate
Description: Adenosine Triphosphate aerosol

Intervention type: DIAGNOSTIC_TEST
Intervention: capsaicin
Description: capsaicin aerosol

Intervention type: DIAGNOSTIC_TEST
Intervention: capsaicin
Description: capsaicin aerosol

Intervention type: DIAGNOSTIC_TEST
Intervention: capsaicin
Description: capsaicin aerosol
Study: NCT02542462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix®,
Description: Single oral dose of licensed rotavirus vaccine given alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix®, with other routine vaccines
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq®,
Description: Single oral dose of licensed rotavirus vaccine given alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq®, with other routine vaccines
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines
Study: NCT00459407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04281576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L(P)
Description: Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
Study: NCT01712438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cl rhFVIII
Study: NCT04514367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: Intravenous Infusion
Study: NCT00726323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foretinib (formerly GSK1363089 or XL880)
Description: treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foretinib (formerly GSK1363089 or XL880)
Description: treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
Study: NCT01396785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 33525
Description: Daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 14 days
Study: NCT04476680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
Study: NCT03566550

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: Repeated MRI scans imaging digestion of standard meals

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: Repeated MRI scans imaging digestion of standard meals